EU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemeThe European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for Share XEU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemehttps://pharmaphorum.com/news/eu-fines-teva-and-cephalon-e60-5m-for-pay-for-delay-scheme/
NICE backs Lilly’s Emgality for migraine, adding pressure on NovartisUK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for Share XNICE backs Lilly’s Emgality for migraine, adding pressure on Novartishttps://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/
Gilead pays $97m to resolve US illegal kickback claimsGilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a Share XGilead pays $97m to resolve US illegal kickback claimshttps://pharmaphorum.com/news/gilead-pays-97m-to-resolve-us-illegal-kickback-claims/
Teva charged in US price-fixing investigationThe US Department of Justice has charged Teva with conspiring with other pharma companies to fix prices for Share XTeva charged in US price-fixing investigationhttps://pharmaphorum.com/news/teva-charged-in-us-price-fixing-investigation/
Teva shares slide as it faces illegal kickback charges from US governmentShares in Teva were down sharply this week after the US Department of Justice filed a complaint that Share XTeva shares slide as it faces illegal kickback charges from US governmenthttps://pharmaphorum.com/news/teva-shares-slide-as-it-faces-illegal-kickback-charges-from-us-government/
Teva launches digital asthma and COPD rescue inhaler in USTeva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to Share XTeva launches digital asthma and COPD rescue inhaler in UShttps://pharmaphorum.com/news/fda-approves-tevas-digital-asthma-and-copd-rescue-inhaler/
Teva’s Kim Innes on shaping the post-COVID future with the NHSLike all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her Share XTeva’s Kim Innes on shaping the post-COVID future with the NHShttps://pharmaphorum.com/views-analysis-sales-marketing/teva-kim-innes-on-shaping-the-post-covid-future-with-the-nhs/
GSK eyes nasal polyps use for Nucala after trial successGlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation Share XGSK eyes nasal polyps use for Nucala after trial successhttps://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/
Trump pledges access to malaria drug chloroquine for COVID-19President Donald Trump thrust a decades old malaria drug called chloroquine into the forefront of efforts to treat Share XTrump pledges access to malaria drug chloroquine for COVID-19https://pharmaphorum.com/news/trump-pledges-access-to-malaria-drug-chloroquine-for-covid-19/
